Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies

References

• Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the hereditary angioedema international working group. Allergy: Eur J Allergy Clin Immunol. 2014;69(5):602–616. doi: 10.1111/all.12380
   Google Scholar
• Longhurst HJ, Bork K. Hereditary angioedema: an update on causes, manifestations and treatment. Br J Hosp Med. 2019;80(7):391–398. doi: 10.12968/hmed.2019.80.7.391
   PubMed Web of Science ®Google Scholar
• Caccia S, Suffritti C, Cicardi M. Pathophysiology of hereditary angioedema. Pediatr Allergy Immunol Pulmonol. 2014;27(4):159–163. doi: 10.1089/ped.2014.0425
   PubMed Web of Science ®Google Scholar
• Wu MA, Tsvirkun D, Bureau L, et al. Paroxysmal permeability disorders: development of a microfluidic device to assess endothelial barrier function. Front Med. 2019;6:1–7. doi: 10.3389/fmed.2019.00089
   Web of Science ®Google Scholar
• Debreczeni ML, Németh Z, Kajdácsi E, et al. Molecular Dambusters: what is behind hyperpermeability in bradykinin-mediated angioedema? Clin Rev Allergy Immunol. 2021;60:318–347. doi: 10.1007/s12016-021-08851-8
   PubMed Web of Science ®Google Scholar
• Bryant J, Shariat-Madar Z. Human plasma kallikrein-kinin system: physiological and biochemical parameters. Cardiovasc Hematol Agents Med Chem. 2009;7(3):234–250. doi: 10.2174/187152509789105444
   PubMedGoogle Scholar
• Kaplan AP, Joseph K. Pathogenesis of hereditary angioedema: the role of the Bradykinin-Forming Cascade. Immunol Allergy Clin North Am. 2017;37:513–525. doi: 10.1016/j.iac.2017.04.001
   PubMed Web of Science ®Google Scholar
• Ghebrehiwet B, Kaplan AP, Joseph K, et al. The complement and contact activation systems: partnership in pathogenesis beyond angioedema. Immunol Rev. 2016;274(1):281–289. doi: 10.1111/imr.12469
   PubMed Web of Science ®Google Scholar
• Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy: Eur J Allergy Clin Immunol. 2017;72(2):300–313. doi: 10.1111/all.13001
   Google Scholar
• Betschel S, Badiou J, Binkley K, et al. The International/Canadian hereditary angioedema guideline. Allergy, Asthma Clin Immunol. 2019;15(1):1–29. doi: 10.1186/s13223-019-0376-8
   PubMed Web of Science ®Google Scholar
• Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124(4):801–808. doi: 10.1016/j.jaci.2009.07.017
   PubMed Web of Science ®Google Scholar
• Bruce L, Zuraw MD, Paula J, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363(6):513–522. doi: 10.1056/NEJMoa0805538
   PubMed Web of Science ®Google Scholar
• Craig T, Zuraw B, Longhurst H, et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2019;7(6):1793–1802.e2. doi: 10.1016/j.jaip.2019.01.054
   PubMed Web of Science ®Google Scholar
• Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. Journal Of Allergy And Clinical Immunology. 2010;126(4):821–827.e14. doi: 10.1016/j.jaci.2010.07.021
   PubMed Web of Science ®Google Scholar
• Farkas H. Icatibant as acute treatment for hereditary angioedema in adults. Expert Rev Clin Pharmacol. 2016;9(6):779–788. doi: 10.1080/17512433.2016.1182425
   PubMed Web of Science ®Google Scholar
• Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:523–529. doi: 10.1016/j.anai.2010.04.012
   PubMed Web of Science ®Google Scholar
• Banerji A, Bernstein JA, Johnston DT, et al. Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE study. Allergy: Eur J Allergy Clin Immunol. 2022;77(3):979–990. doi: 10.1111/all.15011
   Google Scholar
• Riedl MA, Maurer M, Bernstein JA, et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy: Eur J Allergy Clin Immunol. 2020;75(11):2879–2887. doi: 10.1111/all.14416
   Google Scholar
• Ohsawa I, Honda D, Suzuki Y, et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy: Eur J Allergy Clin Immunol. 2021;76(6):1789–1799. doi: 10.1111/all.14670
   Google Scholar
• Farkas H, Stobiecki M, Peter J, et al. Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study. Clin Transl Allergy. 2021;11(4):11. doi: 10.1002/clt2.12035
   Web of Science ®Google Scholar
• Pharmaceuticals A. Attune pharmaceuticals announces pre-clinical data for ATN-249, an oral plasma kallikrein inhibitor for the treatment of HAE at AAAAI. http://attunepharma.com/media/[Internet]https://ejournal.poltektegal.ac.id/index.php/siklus/article/view/298 http://repositorio.unan.edu.ni/2986/1/5624.pdf http://dx.doi.org/10.1016/j.jana.2015.10.005 http://www.biomedcentral.com/1471-2458/12/58 http://ovidsp.ovid.com/ovidweb.cgi?T=JS&P
   Google Scholar
• Hofman ZLM, Clark CC, Hack CE, et al. Detecting oral kallikrein-targeting therapy through triggered contact activation: a phase I study. Journal Of Allergy And Clinical Immunology. 2020;146(6):1446–1449.e5. doi: 10.1016/j.jaci.2020.03.038
   PubMed Web of Science ®Google Scholar
• Attune Pharmaceuticals. Attune pharmaceuticals announces positive phase 1 results for ATN-249, an oral plasma kallikrein inhibitor for the treatment of HAE. 2019. http://attunepharma.com/assets/Attune-Phase-1_2019_01_22.pdfchrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/http://attunepharma.com/assets/Attune-Phase-1_2019_01_22.pdf
   Google Scholar
• Kalfus I, Ofman E, McDonald A. Pharmacokinetics, safety, and potency of ATN-249, a novel oral plasma kallikrein inhibitor for hereditary angioedema. Allergy, Asthma Clin Immunol. 2019;15:249. https://www.embase.com/search/results?subaction=viewrecord&id=L629324253&from=export%0A10.1186/s13223-019-0355-0
   Google Scholar
• Pharmaceuticals AK, Pharmaceuticals K, Statements F, et al. KalVista pharmaceuticals announces termination of kvd824 phase 2 komplete trial for prophylactic treatment of hereditary angioedema | kalvista pharmaceuticals. Inc. 2024 https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-termination-kvd824-phase-2/.
   Google Scholar
• Maetzel A, Smith MD, Duckworth EJ, et al. KVD900, an oral on-demand treatment for hereditary angioedema: phase 1 study results. J Allergy Clin Immunol. 2022;149:2034–2042. doi: 10.1016/j.jaci.2021.10.038
   PubMed Web of Science ®Google Scholar
• Aygören-Pürsün E, Zanichelli A, Cohn DM, et al. An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial. Lancet. 2023;401(10375):458–469. doi: 10.1016/S0140-6736(22)02406-0
   PubMed Web of Science ®Google Scholar
• Duckworth EJ, Murugesan N, Li L, et al. Pharmacological suppression of the kallikrein kinin system with KVD900: an orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema. Clin Exp Allergy. 2022;52(9):1059–1070. doi: 10.1111/cea.14122
   PubMed Web of Science ®Google Scholar
• Ferrone JD, Bhattacharjee G, Revenko AS, et al. IONIS-PKK Rx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production. Nucleic Acid Ther. 2019;29(2):82–91. doi: 10.1089/nat.2018.0754
   PubMed Web of Science ®Google Scholar
• Cohn DM, Viney NJ, Fijen LM, et al. Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema. N Engl J Med. 2020;383(13):1242–1247. doi: 10.1056/NEJMoa1915035
   PubMed Web of Science ®Google Scholar
• Fijen LM, Riedl MA, Bordone L, et al. Inhibition of Prekallikrein for Hereditary Angioedema. N Engl J Med. 2022;386(11):1026–1033. doi: 10.1056/NEJMoa2109329
   PubMed Web of Science ®Google Scholar
• Veronez CL, Aabom A, Martin RP, et al. Genetic variation of kallikrein-kinin system and related genes in patients with hereditary angioedema. Front Med. 2019;6:1–6. doi: 10.3389/fmed.2019.00028
   Web of Science ®Google Scholar
• Longhurst H. Transient exposure to NTLA-2002, an investigational CRISPR/Cas9-based gene editing therapy, leads to durable pharmacodynamic responses and attack control in patients with hereditary angioedema [13th C1-inhibitor deficiency and angioedema workshop—2023]. Allergy, Asthma Clin Immunol. 2023;19(Suppl1).
   Google Scholar
• Matthews A, Higgins E. Astria therapeutics announces positive preliminary results from the phase 1a clinical trial of STAR-0215 in healthy subjects investor relations. 2024;1–2. https://ir.astriatx.com/news-releases/news-release-details/astria-therapeutics-announces-positive-preliminary-results-phase
   Google Scholar
• Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—the 2021 revision and update. Allergy: Eur J Allergy Clin Immunol. 2022;77(7):1961–1990. doi: 10.1111/all.15214
   Google Scholar
• Craig T, Magerl M, Levy DS, et al. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2022;399(10328):945–955. doi: 10.1016/S0140-6736(21)02225-X
   PubMed Web of Science ®Google Scholar
• Craig TJ, Reshef A, Li HH, et al. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10382):1079–1090. doi: 10.1016/S0140-6736(23)00350-1
   PubMed Web of Science ®Google Scholar
• Riedl M, Bernstein JA, Machnig T, et al. Haermony-1: clinical study of adeno associated virus vectormediated gene therapy of human C1-inhibitor in hereditary angioedema type I and II [13th C1 ‑ inhibitor deficiency and angioedema workshop—2023]. Allergy, Asthma Clin Immunol. 2023;19(Suppl1).
   PubMedGoogle Scholar